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Nuclear medicine is an integral part of modern healthcare. It
uses biomolecules tagged with radioactive isotopes that can
recognize different molecular targets in the body or seek out
hallmarks of malignant and benign conditions. The distribu-
tion of trace amounts of a radioactively labelled molecule,
known as a radiotracer, can be mapped and followed non-
invasively anywhere in the human body using a dedicated
system, such as a single photon emission computed tomogra-
phy (SPECT) system or a positron emission tomography
(PET) system. This trace approach provides longitudinal sets
of volumetric and quantitative images that can be used to
diagnose a wide range of diseases and/or assess response to
disease-specific treatments. Replacing these diagnostic radio-
nuclides with alternative nuclides that emit a different type of
radiation converts imaging tracers into drugs that deliver
potent and targeted molecular treatment. Recent advances
have extended the range of molecular radiotherapies, which
are now applied across a broad spectrum of diseases from
arthritis and benign thyroid diseases to many types of cancer.
As such, nuclear medicine is in a key position to bring per-
sonalized or image-guided therapy into routine clinical
practice.
This key position is supported by the rapidly expanding
fields of radiochemistry and radiopharmacy with novel kit-
like or cassette-type labelling techniques which allow shorter
turn-around times from the identification of therapeutic targets
to the design and evaluation of associated radiotracers,
resulting in lower development costs. Over the past 5 years,
significant technological breakthroughs in imaging hardware
and image processing algorithms have also been introduced,
enabling specific radiotracer imaging for improved character-
ization of targeted cellular and functional processes in clinical
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routine. Recent advances in PET detector design have resulted
in tomographs with improved lesion detection capabilities
through better contrast and spatial resolution performance,
that can also be attributed to the incorporation of stable time-
of-flight (ToF) performance and larger axial fields-of-view.
In parallel with these hardware developments, advanced
implementations of updated image reconstruction algorithms
have further improved image quality and, just as importantly,
quantitative performance. Associated developments include
spatial resolution modelling, incorporation of prior object
information in the reconstruction algorithms, better motion
estimation and correction, and improved scatter correction
using simulations and anatomical priors. When combined
with highly specific radiopharmaceuticals with elevated
target-to-background ratios, these technological advances will
significantly increase detectability of very small lesions and
visualization of small cerebral structures. Furthermore, in-
creased system sensitivity will enable higher patient through-
put or the application of more sophisticated PET protocols,
such as dynamic PET or multitracer scans, keeping clinical
throughput the same.
Likewise, the range of applications of SPECT imaging has
benefited from the adoption of solid-state detectors (e.g.
CdZnTe) that provide better energy resolution and, if incorpo-
rated into organ-specific SPECT systems, higher volume sensi-
tivity than scintillator-based detector systems. For applications
in nuclear cardiology the higher system sensitivity translates into
very short acquisition times of around 2 min or, if acquisition
time remains unchanged, in significantly reduced patient expo-
sure of less than 1 mSv for a myocardial SPECT examination.
Next to technical developments and impressive advances
in diagnostic quality, nuclear medicine also adds to the
armamentarium of therapeutic options through the concept
of theranostics, a combination of therapy and diagnostics
using the same biomolecule labelled with different radio-
isotopes to provide inherently synergistic imaging and ther-
apy. Next to treating thyroid cancer, the validity of
theranostics in modern healthcare has been demonstrated
in neuroendocrine tumours (NET). Here, somatostatin ana-
logues are used as ligands and 68Ga/90Y or 68Ga/177Lu as
pairs of diagnostic/therapeutic radionuclides. In patients
with progressive NET, fractionated, personalized peptide
radioreceptor therapy (PRRT) with lower doses of radioac-
tivity given over an extended period of time results in
excellent therapeutic responses. At the same time, severe
haematological and renal toxicities are reduced resulting in
a significant improvement in quality of life. PRRT has also
proven to be highly effective in the management of ad-
vanced NET. These facts attest to the power of personal-
ized medicine. This concept is further strengthened by
recognizing the importance of visualizing molecular thera-
peutic targets, such as the expression of hormone receptors
in breast cancer, for improved patient and therapy selection.
Furthermore, recent progress in genomic exploration of
cancers as well as in detection of circulating cancer cells
or abnormal DNA and mRNA has been demonstrated, thus,
rendering in vivo nuclear imaging as a core technique for
whole-body lesion detection and tissue characterization.
In summary, nuclear medicine provides non-invasive tools
to monitor and predict responses to therapy. As such, it gives
an opportunity to select the best therapy for the individual
patient. Ultimately, this will lead to improved quality of life
and, at the same time, a reduction in healthcare costs.
While this is not new to members of the nuclear
medicine community, it must be recognized that nuclear med-
icine is still seen as something obscure or even dangerous.
Therefore, there is a need to align internally and champion the
following key messages:
1. Molecular imaging is effective and safe in diagnosis,
staging, prognostication and follow-up of many clinical
indications
This has been demonstrated in prospective trials of
[18F]FDG PET in lung cancer (diagnosis, staging and
outcome prediction) and lymphoma patients (therapy re-
sponse). These studies also demonstrated a clear diagnos-
tic benefit over anatomical imaging (CT, MRI) alone.
Through the application of only trace amounts of
radiolabelled biomolecules at picomolar concentrations,
PET imaging does not affect patient safety, as has been
known since the early 1980s. Likewise, large-scale nucle-
ar medicine therapy studies with β-emitters including 131I
and 177Lu have shown only minor levels of side effects if
any.
2. Molecular imaging can avoid unnecessary treatments and
reduces patient discomfort and side effects
Nuclear medicine molecular imaging methods enable
the selection of patients for targeted therapies by proving
the presence or absence of therapeutic targets in vivo. For
example, several [18F] fluoroestradiol imaging studies of
the oestrogen receptor status have consistently shown
high negative predictive value: in the absence of signifi-
cant tracer accumulation, the probability of response to
endocrine therapy is very low and alternative therapy
approaches should be considered, thereby avoiding un-
necessary drug treatment and its associated side effects.
Similar observations have also been reported for
[89Zr]trastuzumab and receptor-specific tracers, which
however still lack systematic investigation using struc-
tured prospective trials.
3. Molecular imaging helps individualize patient treatment
Through growing evidence from genetic profiling it is
understood that cancer is not a single homogeneous disease,
but that it is represented by amultitude of genetic alterations
and changes at the cellular level. Adenocarcinomas of the
lung, for example, can contain several different gene
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mutations such as BRAF, EGFR, KRAS or others, all of
which require different treatment strategies.
Today the identification of potential therapeutic targets
requires biopsies of randomly assigned tumour regions,
whole tumours and multiple tumour lesions. Modern nu-
clear medicine techniques enable serial and non-invasive
visualization of functional pathologies at a molecular level.
Therefore, imaging modalities such as PET and SPECTare
the most appropriate techniques for patient-centred tissue
characterization prior to and following therapy.
4. Molecular imaging can help reduce healthcare costs
Pioneering work on cost effectiveness of nuclear med-
icine studies has been performed in the field of nuclear
cardiology, where it was clearly shown that a clinical
approach including myocardial scintigraphy as a gate-
keeper for invasive coronary angiography or revasculari-
zation results in significant cost savings while offering
patients a clear outcome benefit. There is similar evidence
for the diagnosis and treatment of patients lung cancer.
5. Theranostics is a concept unique to nuclear medicine
Molecular imaging and therapy (also known as therapy
and diagnostics: theranostics) using the same biomolecule
labelled with two different radioisotopes is a concept
unique to nuclear medicine. Examples include
radiopeptides such as the somatostatin analogues and
PSMA, monoclonal antibodies against CD20, the combi-
nation of bone scintigraphy and 223Ra therapy of bone
metastases, and radionuclide imaging and therapies using
123I and 131I, respectively.
Nuclear medicine techniques are vital for the development
of new drugs and to accelerate research into future treatments
of disorders including schizophrenia, movement disorders,
Alzheimer ’s disease, coronary artery disease and
inflammatory/infectious disease. Associated registration stud-
ies entail multicentre effort and therefore require support from
independent clinical bodies, such as the EORTC, whilst fi-
nancial backing from international organizations, industry
and, ideally, health insurance companies is also needed.
Molecular imaging is effective and safe for the diagnosis,
staging, prognostication and follow-up of many clinical
indications. Molecular imaging is a medical imaging modality
that helps distinguish early responders from nonresponders,
thus, saving patients from unnecessary treatments, which in
turn reduces patient discomfort and side effects. This may be
the most effective way to personalize therapy to cut down on
the waste of financial healthcare resources associated with the
prescription of expensive therapies for patients without
knowing whether they have the appropriate disease genotype
that many newer therapies are targeting. “What you see is
what you treat” should be the overarching objective of our
efforts. For sure, this is a very facile statement whilst being
easy to comprehend by politicians and health insurance
companies.
Irrespective of the perceived and known strengths of our
field, the nuclear medicine community should align and to-
gether with oncologists, haematologists, endocrinologists and
other therapy specialists advocate a policy change in order to
lessen the stringent requirements for clinical adoption of new
radiopharmaceuticals. There is an urgent need to increase the
awareness of the full scope of nuclear methodology. This
requires active communication and co-operation with other
medical disciplines and associations, much like participation
in lobbying efforts. The failing clinical acceptance of
[90Y] Zevalin (anti-CD20) therapy, for example, has conclu-
sively shown that co-operation with the referring physicians is
at least as important as proof-of-concept evidence in high
quality trials. Therefore, active involvement and improved
communication among referring physicians, nuclear medicine
specialists and industrial partners is essential.
Quantitative and molecular nuclear medicine imaging
should be an integral part of the design of intelligent, cost-
effective clinical trials at the cutting edge of research. It does
not need an evangelist to relay this message, but each of us
should act as a champion of an exciting and rewarding med-
ical discipline.
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